AUG 06, 2016 2:04 PM PDT

New Immunotherapy Strategy Against Lymphoma

WRITTEN BY: Xuan Pham
In an effort to nip lymphomas before it becomes lethal to patients, scientists at the University of Geneva have developed a new way to block the cancer’s migration. This process locks the cancer cells and prevents spread to the lymphatic system.

Blocking the migration of cancer cells to destroy them | Image: University of Geneva
 
Cancer of the blood can be a frightening diagnosis. Lymphomas occur when lymphocytes (white blood cells) turn malignant. It usually starts in a lymphoid organ, such as the lymph node, spleen, or bone marrow, and then infiltrates other organs and tissues. The Leukemia and Lymphoma Society estimates that over 81,000 new patients will be diagnosed with lymphoma this year in the U.S.
 
Malignant lymphocytes become dangerous when they circulate in the blood and travel to the lymphatic system. There, the cancerous cells can cause swelling of the lymph nodes and disrupt normal metabolic processes.
 
But before they arrive at the lymph system, scientists say the cancerous lymphocytes are not yet dangerous. “Since they cannot survive in the blood for long, these malignant cells are compelled to find a more accommodating environment - such as the lymphatic system - where they can proliferate,” said Thomas Matthes, professor at the University of Geneva and senior study author. “We decided to focus on this Achilles heel by containing them in the blood so as to prevent any resulting harm,” he further explained.
 

 Indeed, the team learned that cancerous lymphocytes leave the confines of the blood vessels by expressing a surface protein known as JAM-C. This protein acts like a pass, allowing the mutant cells to get through the endothelial cells that line blood vessels.
 
The team then developed an antibody against JAM-C. This protein targets JAM-C and essentially makes the surface protein unrecognizable to the endothelial cell guards. Essentially, the antibody, named H225, revoked the mutant cells’ ability to migrate out of blood vessels.
 
In experiments, the team showed H225 decreased the cancer cells’ migration to the lymphs by over 50 percent. “H225 also significantly limited cell proliferation, even when tumor cells had already settled in the lymphatic system. In our mice, we observed the nearly-complete disappearance of already-present tumor cells in the organs,” Matthes added.
 
There are nearly 790,000 people currently living with, or recovering from, lymphoma in the U.S. The survival rate from lymphoma is increasing, but only thanks to new research such as this that exploit the cancer’s weaknesses to patients’ advantage. 

Additional source: University of Geneva press release
 
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
NOV 29, 2019
Immunology
NOV 29, 2019
Protecting Killer Immune Cells from Themselves
Destroying human cells compromised by viruses and cancer is the name of the game for so-called “killer” cells of the immune system. They employ...
DEC 02, 2019
Cancer
DEC 02, 2019
What patients don't know: the side effects of cancer treatment
If anyone you know has ever had to go through treatment for cancer, or if you yourself have had to, you know that fighting the cancer is only part of the b...
JAN 02, 2020
Cancer
JAN 02, 2020
The new "tumor-on-a-chip"
In order to mimic the microenvironment of a tumor in the human body, researchers from Kyoto University have developed a device that they are describing as ...
JAN 16, 2020
Cancer
JAN 16, 2020
FLASH proton therapy: faster and more effective
A new technique called FLASH proposes a new type of radiation therapy. The technique is composed of an ultra-high dose rate of radiotherapy and uses electr...
JAN 20, 2020
Neuroscience
JAN 20, 2020
Ovarian Cancer Protein Accelerates Alzheimer's Neurodegeneration
Around 21,000 people in the US are diagnosed with ovarian cancer every year, while an estimated 5.8 million Americans have Alzheimer’s. Now, research...
FEB 10, 2020
Cancer
FEB 10, 2020
New hope for KRAS-mutant pancreatic cancers
A study published recently in the journal Cancer Research showcases the findings from new research on pancreatic cancer. The study was led by Frank Mc...
Loading Comments...